These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 25962689)
1. Testing drug additivity based on monotherapies. Yang H; Novick SJ; Zhao W Pharm Stat; 2015; 14(4):332-40. PubMed ID: 25962689 [TBL] [Abstract][Full Text] [Related]
3. A curve similarity approach to parallelism testing in bioassay. Faya P; Rauk AP; Griffiths KL; Parekh B J Biopharm Stat; 2020 Jul; 30(4):721-733. PubMed ID: 32163316 [TBL] [Abstract][Full Text] [Related]
4. Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves. Fang HB; Tian GL; Li W; Tan M J Biopharm Stat; 2009 Jul; 19(4):625-40. PubMed ID: 20183430 [TBL] [Abstract][Full Text] [Related]
5. Testing for parallelism in the heteroscedastic four-parameter logistic model. Sidik K; Jonkman JN J Biopharm Stat; 2016; 26(2):250-68. PubMed ID: 25629201 [TBL] [Abstract][Full Text] [Related]
6. A fast and reliable test for parallelism in bioassay. Novick S; Yang H J Biopharm Stat; 2019; 29(6):1011-1023. PubMed ID: 30712462 [TBL] [Abstract][Full Text] [Related]
7. Equivalence testing for parallelism in the four-parameter logistic model. Jonkman JN; Sidik K J Biopharm Stat; 2009 Sep; 19(5):818-37. PubMed ID: 20183446 [TBL] [Abstract][Full Text] [Related]
8. Fitting models for the joint action of two drugs using SAS. Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217 [TBL] [Abstract][Full Text] [Related]
9. A hybrid Bayesian adaptive design for dose response trials. Chang M; Chow SC J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172 [TBL] [Abstract][Full Text] [Related]
11. A simple test for synergy for a small number of combinations. Novick SJ Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140 [TBL] [Abstract][Full Text] [Related]
12. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Boik JC; Newman RA; Boik RJ Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754 [TBL] [Abstract][Full Text] [Related]
13. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies. Holt MM; Stamey JD; Seaman JW; Young DM J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471 [TBL] [Abstract][Full Text] [Related]
14. Parallelism in practice: approaches to parallelism in bioassays. Fleetwood K; Bursa F; Yellowlees A PDA J Pharm Sci Technol; 2015; 69(2):248-63. PubMed ID: 25868991 [TBL] [Abstract][Full Text] [Related]
15. A simple Bayesian decision-theoretic design for dose-finding trials. Fan SK; Lu Y; Wang YG Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943 [TBL] [Abstract][Full Text] [Related]
16. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables. Jiang Z; Song Y; Shou Q; Xia J; Wang W Trials; 2014 Dec; 15():500. PubMed ID: 25528466 [TBL] [Abstract][Full Text] [Related]
18. Sample size adaptation in fixed-dose combination drug trial. James Hung HM; Wang SJ J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108 [TBL] [Abstract][Full Text] [Related]
19. Interaction index and different methods for determining drug interaction in combination therapy. Lee JJ; Kong M; Ayers GD; Lotan R J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394 [TBL] [Abstract][Full Text] [Related]
20. A generalized response surface model with varying relative potency for assessing drug interaction. Kong M; Lee JJ Biometrics; 2006 Dec; 62(4):986-95. PubMed ID: 17156272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]